CNBC Halftime Report Final Trades: EQT Corp., Eli Lilly, Quest Diagnostics & Northrop Grumman

For the first quarter of 2023, the Company expects revenue of approximately $2.4 billion. First quarter 2023 GAAP net loss is expected to approximate $86 million, with GAAP diluted loss per share expected to approximate $1.12. First quarter 2023 adjusted EBITDA is expected to approximate $100 million or 4.2% of revenue, with adjus